Chronic sclerodermic graft-versus-host disease refractory to immunosuppressive treatment responds to UVA1 phototherapy
Authors:
- Stefanie BehrensSBStefanie Behrens
- Claus GrussCGClaus Gruss
- Petra GottlberPGPetra Gottlber
- Ralf Uwe PeterRPRalf Uwe Peter
- Martina KerscherMKMartina Kerscher
- 1 January 2000
- journal article
- case report
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 42 (1) , 134-136
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Etretinate Therapy for Refractory Sclerodermatous Chronic Graft-Versus-Host DiseaseBlood, 1999
- Low-dose UVA1 phototherapy for treatment of localized sclerodermaJournal of the American Academy of Dermatology, 1998
- Induction of interstitial collagenase (MMP-1) by UVA-1 phototherapy in morphea fibroblastsThe Lancet, 1997
- High-dose UVA1 radiation therapy for localized sclerodermaJournal of the American Academy of Dermatology, 1997
- Mycophenolate mofetilThe Lancet, 1996
- Treatment of localised scleroderma by UVA1 phototherapyThe Lancet, 1995
- UVA irradiation induces collagenase in human dermal fibroblasts in vitro and in vivoArchives of Dermatological Research, 1991
- Graft-versus-Host DiseaseNew England Journal of Medicine, 1991
- Photochemotherapy improves chronic cutaneous graft-versus-host diseaseJournal of the American Academy of Dermatology, 1990